What Is Wegovy For? The Two FDA-Approved Indications and How the Mechanism Drives Both

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Wegovy (semaglutide 2.4 mg) is FDA-approved for chronic weight management in adults with BMI ≥30 or BMI ≥27 with weight-related comorbidities, and for cardiovascular risk reduction in adults with established cardiovascular disease and either obesity or overweight
• The medication works through GLP-1 receptor activation in the brain's appetite centers, pancreatic beta cells, and gastrointestinal tract, producing an average 15% total body weight loss over 68 weeks in the STEP 1 trial
• The 2023 SELECT trial established cardiovascular benefit independent of weight loss, showing a 20% reduction in major adverse cardiovascular events in patients with pre-existing heart disease
• Wegovy is not approved for type 2 diabetes treatment (that's Ozempic, a different dose of the same molecule), prediabetes, PCOS, or cosmetic weight loss in individuals without qualifying BMI or comorbidities

Direct answer (40-60 words)

Wegovy is FDA-approved for two indications: chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity, and reduction of cardiovascular death, heart attack, and stroke risk in adults with established cardiovascular disease and either obesity or overweight. It works by mimicking GLP-1, a hormone that regulates appetite and blood sugar.

Table of contents

1. The two FDA-approved indications for Wegovy
2. The mechanism: how semaglutide produces weight loss
3. What most articles get wrong about GLP-1 receptor distribution
4. The cardiovascular indication: why SELECT changed the conversation
5. Who qualifies for Wegovy under FDA labeling
6. The weight-loss data: what "average 15% loss" actually means
7. Off-label uses: what Wegovy is prescribed for but not approved for
8. Wegovy vs Ozempic: same molecule, different indication
9. When Wegovy is the wrong tool: the steelman case against using it
10. The decision framework: determining if Wegovy fits your situation
11. What we see in FormBlends compounded semaglutide prescribing patterns
12. FAQ
13. Sources

The two FDA-approved indications for Wegovy

Wegovy received FDA approval for two distinct indications, granted at different times based on separate clinical trial programs.

Indication 1: Chronic weight management (approved June 2021)

Wegovy is approved as an adjunct to reduced-calorie diet and increased physical activity for chronic weight management in adults with:

• Initial body mass index (BMI) of 30 kg/m² or greater (obesity), OR
• Initial BMI of 27 kg/m² or greater (overweight) in the presence of at least one weight-related comorbid condition

Qualifying comorbidities include hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, and cardiovascular disease.

The approval was based primarily on the STEP clinical trial program (STEP 1 through 5), which enrolled 4,567 adults across multiple studies. The phase 3 STEP 1 trial showed 14.9% mean weight loss at 68 weeks vs 2.4% with placebo (Wilding et al., New England Journal of Medicine, 2021).

Indication 2: Cardiovascular risk reduction (approved March 2024)

Wegovy is approved to reduce the risk of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke in adults with established cardiovascular disease and either obesity or overweight.

This indication was added based on the SELECT trial, a cardiovascular outcomes study that enrolled 17,604 adults age 45 or older with pre-existing cardiovascular disease (prior heart attack, stroke, or peripheral artery disease) and BMI ≥27. The trial showed a 20% relative risk reduction in major adverse cardiovascular events (MACE) over a median 40 months (Lincoff et al., New England Journal of Medicine, 2023).

The cardiovascular indication is notable because the benefit appeared independent of the degree of weight loss achieved. Patients who lost minimal weight still showed cardiovascular benefit, suggesting GLP-1 receptor agonism has direct vascular and inflammatory effects beyond weight reduction.

The mechanism: how semaglutide produces weight loss

Semaglutide is a GLP-1 receptor agonist. GLP-1 (glucagon-like peptide-1) is a naturally occurring incretin hormone produced by L-cells in the small intestine in response to food intake. Native GLP-1 has a half-life of about 2 minutes because it's rapidly degraded by the enzyme DPP-4. Semaglutide is a modified version with a half-life of approximately 7 days, allowing once-weekly dosing.

The weight loss mechanism operates through four primary pathways:

1. Central appetite suppression

GLP-1 receptors are densely concentrated in the hypothalamus and brainstem, particularly the arcuate nucleus and area postrema. When semaglutide binds these receptors, it reduces hunger signaling and increases satiety signaling. Functional MRI studies show reduced activation in brain reward centers in response to food cues in patients on semaglutide (van Bloemendaal et al., Diabetes Care, 2014).

The subjective experience is reduced food noise (constant thoughts about eating), earlier satiety (feeling full after smaller portions), and reduced reward response to high-calorie foods.

2. Delayed gastric emptying

GLP-1 receptors in the stomach and pyloric sphincter slow the rate at which food moves from the stomach into the small intestine. Normal gastric emptying half-time is 90 to 120 minutes. On therapeutic-dose semaglutide, this extends to 3 to 4 hours (Hjerpsted et al., Diabetes Obesity and Metabolism, 2018).

Slower gastric emptying prolongs the sensation of fullness and reduces the volume of food consumed at subsequent meals. This is the same mechanism responsible for the nausea and reflux side effects common during titration.

3. Glucose-dependent insulin secretion

GLP-1 receptors on pancreatic beta cells stimulate insulin release only when blood glucose is elevated. This improves glycemic control without causing hypoglycemia in non-diabetic patients. Better glucose regulation reduces hunger spikes caused by reactive hypoglycemia after high-carbohydrate meals.

4. Reduced glucagon secretion

GLP-1 suppresses glucagon release from pancreatic alpha cells. Glucagon normally signals the liver to release stored glucose. Lower glucagon means less glucose output from the liver, contributing to improved metabolic health and reduced hunger between meals.

The net effect across these four pathways is a 20% to 35% reduction in caloric intake without conscious restriction, according to ad libitum feeding studies (Friedrichsen et al., Diabetes Obesity and Metabolism, 2021).

What most articles get wrong about GLP-1 receptor distribution

Most patient-facing content describes GLP-1 medications as "appetite suppressants" or "diabetes drugs," implying the receptors are primarily in the brain or pancreas. This is incomplete and misleading.

GLP-1 receptors are distributed across at least 15 tissue types, including:

• Hypothalamus and brainstem (appetite regulation)
• Pancreatic beta and alpha cells (glucose homeostasis)
• Stomach and intestinal smooth muscle (motility)
• Heart and vascular endothelium (cardiovascular effects)
• Kidneys (sodium handling and blood pressure)
• Liver (lipid metabolism)
• Adipose tissue (lipolysis signaling)

The error matters because it shapes patient expectations. If you think Wegovy is "just" an appetite suppressant, you expect hunger reduction and nothing else. When you experience fatigue during the first month (common, related to caloric deficit and metabolic adaptation), or notice blood pressure dropping (GLP-1 has natriuretic effects), or develop reflux (delayed gastric emptying), these seem like mysterious side effects rather than predictable consequences of systemic GLP-1 receptor activation.

The SELECT trial's cardiovascular benefit independent of weight loss is direct evidence that GLP-1 receptor agonism is doing more than suppressing appetite. Proposed mechanisms include reduced vascular inflammation (measured by hsCRP reduction), improved endothelial function, reduced platelet aggregation, and favorable changes in adipokine signaling (Marso et al., New England Journal of Medicine, 2016).

Calling semaglutide an appetite suppressant is like calling aspirin a headache pill. Technically true for one indication, but it misses the systemic pharmacology.

The cardiovascular indication: why SELECT changed the conversation

The SELECT trial (Semaglutide Effects on Heart Disease and Stroke in Patients with Overweight or Obesity) was designed to answer whether semaglutide reduces cardiovascular events in patients with established heart disease, independent of diabetes status.

Trial design:

• 17,604 participants, age 45+
• All had prior cardiovascular event (MI, stroke, or symptomatic peripheral artery disease)
• BMI ≥27, no diabetes diagnosis required
• Randomized to semaglutide 2.4 mg weekly or placebo
• Median follow-up 40 months (over 3 years)

Primary outcome (MACE):

• Semaglutide group: 6.5% experienced cardiovascular death, nonfatal MI, or nonfatal stroke
• Placebo group: 8.0%
• Hazard ratio 0.80 (95% CI 0.72-0.90), p<0.001
• 20% relative risk reduction

Key secondary findings:

• Cardiovascular death alone: 2.5% vs 3.0% (HR 0.85)
• All-cause mortality: 4.3% vs 5.2% (HR 0.81)
• Weight loss: mean 9.4% vs 0.9% at 104 weeks
• The cardiovascular benefit curve separated early (within 6 months) and continued diverging throughout the trial

The most important finding was buried in the subgroup analyses: the cardiovascular benefit was present across all weight-loss quartiles. Patients in the lowest quartile of weight loss (those who lost the least weight) still showed cardiovascular benefit comparable to those in the highest quartile.

This suggests GLP-1 receptor agonism has direct cardioprotective effects beyond weight reduction. Proposed mechanisms include:

• Reduced systemic inflammation (hsCRP dropped 39% in SELECT)
• Improved endothelial function and arterial compliance
• Reduced oxidative stress in vascular tissue
• Favorable changes in lipid particle size and number
• Reduced epicardial adipose tissue (fat around the heart)

The SELECT results shifted the medical conversation from "weight-loss drug" to "cardiometabolic medication." For patients with established cardiovascular disease and obesity, Wegovy is now positioned similarly to statins or ACE inhibitors: a medication that reduces hard clinical endpoints (death, heart attack, stroke), not just surrogate markers.

Comparison table: STEP 1 (weight loss) vs SELECT (cardiovascular outcomes)

Trial	Population	Primary endpoint	Semaglutide result	Placebo result	Difference
STEP 1	Adults with obesity, no CVD required	Mean % weight loss at 68 weeks	14.9%	2.4%	12.5 percentage points
SELECT	Adults with CVD + obesity/overweight	MACE rate over 40 months	6.5%	8.0%	20% relative risk reduction

Who qualifies for Wegovy under FDA labeling

The FDA label specifies eligibility criteria based on BMI and comorbidity status.

For the weight management indication:

You qualify if you meet ONE of these criteria:

• BMI ≥30 kg/m² (obesity), regardless of other conditions
• BMI ≥27 kg/m² (overweight) AND at least one weight-related comorbid condition

Qualifying comorbidities include:

• Hypertension (blood pressure ≥130/80 or on antihypertensive medication)
• Type 2 diabetes
• Dyslipidemia (elevated LDL, low HDL, or elevated triglycerides)
• Obstructive sleep apnea
• Cardiovascular disease (prior MI, stroke, heart failure, or angina)

For the cardiovascular risk reduction indication:

You qualify if you meet ALL of these criteria:

• Age 45 or older
• Established cardiovascular disease (prior MI, stroke, or peripheral artery disease)
• BMI ≥27 kg/m²

Who does NOT qualify under FDA labeling:

• BMI <27 (cosmetic weight loss in normal-weight individuals)
• BMI 27-29.9 without any weight-related comorbidity
• Type 1 diabetes (not studied; risk of diabetic ketoacidosis)
• Personal or family history of medullary thyroid carcinoma
• Multiple endocrine neoplasia syndrome type 2 (MEN 2)
• Pregnancy or planned pregnancy within 2 months
• Age <18 (pediatric approval exists for age 12+ but with different labeling)

The BMI thresholds are population-level guidelines. Individual prescribing decisions account for body composition (a muscular athlete with BMI 29 and no comorbidities wouldn't qualify; a patient with BMI 26, prediabetes, and central adiposity might qualify off-label). The FDA label sets the regulatory standard; clinical practice guidelines from obesity medicine societies allow for more nuanced decision-making.

The weight-loss data: what "average 15% loss" actually means

The STEP 1 trial reported mean weight loss of 14.9% at 68 weeks. This number appears in nearly every article about Wegovy, but the mean obscures important distribution details.

STEP 1 weight-loss distribution at 68 weeks (N=1,306 on semaglutide 2.4 mg):

• Lost ≥5% of body weight: 86.4% of participants
• Lost ≥10%: 69.1%
• Lost ≥15%: 50.5%
• Lost ≥20%: 32.0%
• Lost <5%: 13.6% (non-responders)

The distribution is roughly normal with a right tail. About half of patients lose more than 15%, and about a third lose more than 20%. But 1 in 7 patients loses less than 5%, which is within the range of placebo response.

What predicts response?

Post-hoc analyses of STEP trials identified several factors associated with greater weight loss:

• Higher baseline weight (heavier patients lose more absolute pounds but similar percentages)
• Younger age (each decade of age associated with ~1% less weight loss)
• No prior history of multiple failed weight-loss attempts
• Adherence to full 2.4 mg dose (dose-response relationship is strong)
• Concurrent lifestyle modification (diet and exercise counseling improved outcomes by 2-3 percentage points)

Factors NOT predictive of response:

• Sex (men and women respond similarly)
• Race/ethnicity (response consistent across groups)
• Baseline A1C or glucose (diabetic and non-diabetic patients respond similarly)

Time course:

Weight loss is not linear. The typical pattern:

• Weeks 0-8: Rapid loss (0.5-1% per week), mostly during titration
• Weeks 8-28: Continued steady loss (0.3-0.5% per week)
• Weeks 28-52: Slower loss, approaching plateau (0.1-0.2% per week)
• Weeks 52-68: Plateau or minimal additional loss

Maximum weight loss typically occurs between weeks 60 and 68. After that, weight stabilizes if the medication continues, or regains if discontinued (the STEP 4 withdrawal trial showed 14.8% regain over 48 weeks after stopping, Rubino et al., JAMA, 2021).

Off-label uses: what Wegovy is prescribed for but not approved for

Wegovy is frequently prescribed off-label for conditions where weight loss is beneficial but the medication lacks formal FDA approval for that specific indication.

Common off-label uses:

1. Prediabetes prevention Patients with A1C 5.7-6.4% and obesity often receive Wegovy to prevent progression to type 2 diabetes. The mechanism is sound (improved insulin sensitivity, reduced hepatic glucose output), and the STEP program included many patients with prediabetes. But the FDA label doesn't specifically list diabetes prevention as an indication.

2. Polycystic ovary syndrome (PCOS) Weight loss improves insulin resistance, androgen levels, and ovulatory function in PCOS. Small studies show GLP-1 agonists improve metabolic markers in PCOS (Elkind-Hirsch et al., Journal of Clinical Endocrinology and Metabolism, 2008), but no large RCTs exist and the FDA has not approved this indication.

3. Non-alcoholic fatty liver disease (NAFLD/NASH) Weight loss of 10% or more improves liver histology in NASH. The STEP 1 trial showed significant reductions in liver enzymes (ALT, AST). Semaglutide is being studied in dedicated NASH trials, but approval for this indication has not been granted.

4. Weight regain after bariatric surgery Patients who regain weight after gastric bypass or sleeve gastrectomy sometimes receive GLP-1 agonists. The rationale is that post-surgical anatomy may reduce endogenous GLP-1 signaling over time. Limited evidence supports this use (Miras et al., Lancet Diabetes and Endocrinology, 2014).

5. Obesity in adolescents age 12-17 Wegovy is FDA-approved for adolescents age 12+ with obesity (separate approval based on the STEP TEENS trial). This is technically on-label but often described as off-label because many prescribers are unaware of the pediatric indication.

Off-label use FormBlends does not support:

• Cosmetic weight loss in individuals with BMI <27 and no comorbidities
• Eating disorder treatment (GLP-1 agonists can worsen restrictive eating patterns)
• Athletic performance or bodybuilding (no evidence of benefit; potential for muscle loss)

Off-label prescribing is legal and common in medicine. The distinction matters for insurance coverage (off-label uses are often denied) and for informed consent (patients should know when a use lacks formal regulatory review).

Wegovy vs Ozempic: same molecule, different indication

Wegovy and Ozempic both contain semaglutide, but they are distinct products with different FDA approvals, dosing, and labeling.

Comparison table:

Feature	Ozempic	Wegovy
Active ingredient	Semaglutide	Semaglutide
FDA-approved indication	Type 2 diabetes, cardiovascular risk reduction in diabetics	Chronic weight management, cardiovascular risk reduction in patients with obesity/overweight
Available doses	0.25 mg, 0.5 mg, 1 mg, 2 mg	0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg
Maintenance dose	0.5 mg to 2 mg weekly	2.4 mg weekly
Pen design	Multi-dose pen (4 or 8 doses per pen)	Single-dose pen (4 pens per box)
Typical insurance coverage	Covered for diabetes	Covered for obesity if plan includes weight-management benefits (many exclude)

The medications are pharmacologically identical at equivalent doses. A patient taking Ozempic 2 mg is receiving the same drug exposure as someone on Wegovy 2 mg. The difference is regulatory: Ozempic's clinical trial program focused on diabetes and diabetic cardiovascular outcomes (SUSTAIN trials, PIONEER trials). Wegovy's program focused on obesity and obesity-related cardiovascular outcomes (STEP trials, SELECT trial).

Why the distinction matters:

Insurance companies use the FDA indication to determine coverage. Ozempic is covered for diabetes. Wegovy is covered for obesity only if the plan includes weight-management pharmacy benefits, which many employer plans and Medicare Part D explicitly exclude. This creates a coverage gap where patients with obesity but not diabetes cannot access the medication, while patients with both conditions can access Ozempic.

Some prescribers write Ozempic prescriptions for weight loss in non-diabetic patients (off-label use). This is legal but creates ethical and practical issues. The patient may not be informed that they're receiving a diabetes medication off-label. The dose may be capped at 2 mg instead of the 2.4 mg studied for weight loss. And if the prescriber documents a diabetes diagnosis the patient doesn't have to obtain coverage, that's insurance fraud.

The cleaner approach: if the indication is weight management, the medication should be Wegovy (or compounded semaglutide if brand is unaffordable). If the indication is diabetes, the medication should be Ozempic. Using one as a workaround for the other creates documentation and compliance problems.

When Wegovy is the wrong tool: the steelman case against using it

A thoughtful obesity medicine specialist might recommend against Wegovy in several scenarios, even for patients who technically qualify under FDA labeling.

1. Active eating disorder or history of restrictive eating

GLP-1 agonists reduce appetite and delay gastric emptying. In a patient with anorexia nervosa, bulimia, or ARFID (avoidant/restrictive food intake disorder), this can worsen restriction and accelerate malnutrition. The medication doesn't distinguish between pathological restriction and healthy caloric deficit.

The counterargument is that obesity and eating disorders can coexist, and some patients with binge-eating disorder benefit from appetite regulation. But the risk-benefit calculation changes when restriction is the primary pathology. A psychiatric evaluation should precede GLP-1 therapy in anyone with eating disorder history.

2. Inability to afford long-term treatment

Wegovy costs approximately $1,400 per month without insurance. Weight regain after discontinuation is well-documented (the STEP 4 withdrawal trial showed patients regained two-thirds of lost weight within a year of stopping). If a patient can afford 6 months of treatment but not ongoing therapy, the outcome may be net harm: the metabolic and psychological stress of rapid regain can worsen insulin resistance and trigger binge eating.

The ethical question: is it better to lose 15% and regain it, or never lose it at all? The answer depends on whether the patient can use the weight-loss window to establish sustainable lifestyle changes. For most patients, the answer is no. Weight regain is the norm, not the exception, when medication stops.

3. Planned pregnancy within 2 years

Semaglutide has a 5-week washout period (5 half-lives to clear). The FDA recommends stopping 2 months before conception. But the bigger issue is weight regain during pregnancy. If a patient loses 50 pounds on Wegovy, stops for pregnancy, regains 40 pounds during pregnancy, and cannot restart while breastfeeding, the net result may be worse metabolic health than if treatment had never started.

The alternative: delay GLP-1 therapy until after childbearing is complete, or accept that treatment will be intermittent with planned discontinuation and resumption.

4. Severe gastroparesis or prior gastric surgery altering anatomy

Delayed gastric emptying is a feature of GLP-1 agonists, not a bug. But in a patient with pre-existing gastroparesis (diabetic or idiopathic), further slowing can cause intractable nausea, vomiting, and nutritional deficiency. Similarly, patients with prior gastric bypass or sleeve gastrectomy have altered anatomy that may interact unpredictably with GLP-1 effects on motility.

These patients aren't absolutely contraindicated, but they require closer monitoring and often tolerate only low doses.

5. Preference for non-pharmacological intervention

Some patients achieve equivalent weight loss through bariatric surgery, intensive lifestyle intervention, or other medications with different mechanisms (phentermine/topiramate, naltrexone/bupropion). Wegovy is not the only tool, and for some patients it's not the best tool.

Bariatric surgery produces greater weight loss (25-30% at 2 years) and has 30-year outcome data showing sustained benefit. For a 35-year-old with BMI 45 and diabetes, surgery may be a better choice than lifelong medication. The decision depends on surgical risk, patient preference, and insurance coverage.

The steelman case is this: Wegovy is a powerful tool, but it's not universally appropriate. The decision to start should account for eating disorder history, financial sustainability, reproductive plans, GI comorbidities, and alternative options. Prescribing it reflexively to every patient with BMI >30 is poor medicine.

The decision framework: determining if Wegovy fits your situation

Use this branching framework to assess whether Wegovy is appropriate for your specific situation.

Step 1: Do you meet FDA labeling criteria?

• BMI ≥30, OR
• BMI ≥27 with hypertension, diabetes, dyslipidemia, sleep apnea, or CVD

If NO: Wegovy is not indicated. Consider lifestyle intervention, alternative medications, or reassess in 6-12 months.

If YES: Proceed to Step 2.

Step 2: Do you have absolute contraindications?

• Personal or family history of medullary thyroid cancer
• Multiple endocrine neoplasia syndrome type 2 (MEN 2)
• Pregnancy or planned pregnancy within 2 months
• Current severe gastroparesis
• Active eating disorder with restrictive features

If YES to any: Do not start Wegovy. Discuss alternatives with your provider.

If NO to all: Proceed to Step 3.

Step 3: Can you afford long-term treatment?

• Insurance covers Wegovy, OR
• You can afford $1,400/month out-of-pocket indefinitely, OR
• You can access compounded semaglutide at $200-400/month indefinitely

If NO: Weight regain after discontinuation is likely. Consider whether short-term use is worth the regain risk, or explore bariatric surgery (often better insurance coverage).

If YES: Proceed to Step 4.

Step 4: Have you attempted lifestyle modification?

• Structured diet intervention (not just "eating better")
• Regular physical activity (150+ minutes/week)
• Behavioral support (dietitian, health coach, or program)

If NO: Start with 3-6 months of intensive lifestyle intervention. GLP-1 medications work better when combined with lifestyle changes, and some patients achieve goals without medication.

If YES and insufficient response: Proceed to Step 5.

Step 5: Do you have established cardiovascular disease?

• Prior heart attack, stroke, or peripheral artery disease

If YES: Wegovy has proven cardiovascular benefit independent of weight loss. Strong indication.

If NO: Wegovy is still appropriate for weight management, but cardiovascular benefit is not the primary goal.

Step 6: Are you prepared for side effects during titration?

• Nausea (very common, usually transient)
• Diarrhea or constipation (common)
• Reflux (common)
• Fatigue (common during first month)
• Hair thinning (uncommon, related to rapid weight loss)

If NO: Discuss expectations with your provider. Most side effects resolve within 8-12 weeks.

If YES: Wegovy is likely appropriate. Proceed with shared decision-making and informed consent.

What we see in FormBlends compounded semaglutide prescribing patterns

FormBlends connects patients with providers who prescribe compounded semaglutide when brand-name Wegovy is unaffordable or unavailable. Across our platform, we observe consistent patterns in who starts treatment, who continues, and who discontinues.

The typical patient profile:

The median patient starting compounded semaglutide through FormBlends has:

• BMI 32-34 (obesity class I)
• At least one weight-related comorbidity (most commonly hypertension or prediabetes)
• Prior weight-loss attempts including structured diet programs
• Insurance that excludes weight-management medications or requires unaffordable copays
• Age 40-55 (though the range spans 22 to 72)

The adherence pattern:

Patients who reach the 2.4 mg maintenance dose and continue for 6+ months show a consistent trajectory:

• Weeks 0-12: High engagement, frequent check-ins, side effect questions peak
• Weeks 12-24: Stabilization, fewer questions, weight loss continues but slows
• Weeks 24-48: Plateau phase, weight stable, medication becomes routine
• After week 48: Long-term continuation, weight maintained, medication integrated into life

The dropout pattern is bimodal. Early dropouts (weeks 0-8) are usually due to intolerable side effects, most commonly nausea or reflux. Late dropouts (after week 24) are usually financial (can no longer afford treatment) or goal-achieved (patient reaches target weight and wants to attempt maintenance without medication, despite regain risk).

The dose-response observation:

Patients who titrate slowly (spending 8 weeks at each dose level rather than the standard 4 weeks) report fewer side effects but similar weight-loss outcomes by week 40. The slower titration extends the time to maximum dose but improves tolerability. We see this pattern most often in patients over age 60 or those with baseline GI sensitivity.

The combination therapy question:

A subset of patients ask about combining semaglutide with other weight-loss medications (phentermine, topiramate, naltrexone/bupropion). The evidence for combination therapy is limited. Small studies suggest additive benefit, but no large RCTs exist. Most providers on the FormBlends platform prescribe semaglutide as monotherapy unless the patient has already been on a stable dose of another agent.

The cardiovascular patient pattern:

Since the SELECT trial publication in late 2023, we've seen increased prescribing for patients with BMI 27-29 and established cardiovascular disease. These patients often have lower weight-loss goals (5-10% rather than 15-20%) and are motivated primarily by cardiovascular risk reduction rather than weight. This group shows high adherence and low discontinuation rates, consistent with using the medication as a chronic disease management tool rather than a time-limited weight-loss intervention.

This is pattern recognition from clinical practice, not a formal research study. But the consistency across thousands of patient journeys suggests these patterns are generalizable.

FAQ

What is Wegovy approved for by the FDA? Wegovy is FDA-approved for chronic weight management in adults with BMI ≥30 or BMI ≥27 with weight-related comorbidities, and for reducing cardiovascular death, heart attack, and stroke risk in adults with established cardiovascular disease and obesity or overweight.

Is Wegovy only for diabetes? No. Wegovy is not approved for diabetes treatment. It's approved for weight management and cardiovascular risk reduction. Ozempic, a different dose of the same drug, is approved for type 2 diabetes. Wegovy works in non-diabetic patients.

How does Wegovy cause weight loss? Wegovy activates GLP-1 receptors in the brain's appetite centers, reducing hunger and increasing satiety. It also slows gastric emptying, keeping you full longer, and improves glucose regulation, reducing hunger spikes. The combined effect reduces caloric intake by 20-35% without conscious restriction.

How much weight do people lose on Wegovy? In the STEP 1 trial, patients lost an average of 14.9% of body weight over 68 weeks. About half lost more than 15%, and one-third lost more than 20%. About 14% lost less than 5% (non-responders).

Is Wegovy the same as Ozempic? Both contain semaglutide, but they're different products. Ozempic is approved for diabetes at doses up to 2 mg weekly. Wegovy is approved for weight management at 2.4 mg weekly. The molecule is identical, but the indication, dosing, and insurance coverage differ.

Who should not take Wegovy? Wegovy is contraindicated in patients with personal or family history of medullary thyroid cancer, MEN 2 syndrome, pregnancy, or severe gastroparesis. It should be used cautiously in patients with eating disorders, active gallbladder disease, or history of pancreatitis.

Does Wegovy work without diet and exercise? Wegovy produces weight loss even without structured diet and exercise programs, but outcomes improve with lifestyle modification. The FDA label specifies it should be used "as an adjunct to reduced-calorie diet and increased physical activity." Real-world data shows patients who combine medication with lifestyle changes lose 2-3 percentage points more weight.

What happens if I stop taking Wegovy? Weight regain is common after discontinuation. The STEP 4 withdrawal trial showed patients regained about two-thirds of lost weight within 48 weeks of stopping. Appetite and gastric emptying return to baseline within 5-7 weeks after the last dose.

Can Wegovy help with prediabetes? Yes, though this is an off-label use. Weight loss improves insulin sensitivity and reduces progression to type 2 diabetes. The STEP program included many patients with prediabetes, and outcomes showed improved glycemic markers. But Wegovy is not FDA-approved specifically for diabetes prevention.

How long does it take for Wegovy to work? Most patients notice reduced appetite within 1-2 weeks of starting. Measurable weight loss begins by week 4. Maximum weight loss typically occurs between weeks 60 and 68. The medication requires ongoing use to maintain effect.

Does Wegovy reduce heart attack risk? Yes, in patients with established cardiovascular disease. The SELECT trial showed a 20% reduction in major adverse cardiovascular events (heart attack, stroke, cardiovascular death) in patients with pre-existing heart disease and obesity or overweight. The benefit appeared independent of weight loss.

Is Wegovy covered by insurance? Coverage varies. Many insurance plans cover Wegovy for patients meeting FDA criteria, but many employer plans and Medicare Part D exclude weight-management medications. Prior authorization is typically required. Compounded semaglutide is an alternative when brand coverage is denied.

Can I take Wegovy if I have PCOS? Wegovy is not FDA-approved for PCOS, but it's commonly prescribed off-label. Weight loss improves insulin resistance, androgen levels, and ovulatory function in PCOS patients. Discuss with your provider whether the off-label use is appropriate for your situation.

What's the difference between Wegovy and compounded semaglutide? Wegovy is the FDA-approved brand-name product manufactured by Novo Nordisk. Compounded semaglutide is prepared by a state-licensed compounding pharmacy using the same active ingredient. Compounded versions are not FDA-approved, cost less ($200-400/month vs $1,400/month), and are available when brand supply is limited or insurance doesn't cover brand.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine. 2023.
3. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
4. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.
5. Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine. 2016.
6. Hjerpsted JB et al. Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity. Diabetes Obesity and Metabolism. 2018.
7. van Bloemendaal L et al. Effects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS. Journal of Endocrinology. 2014.
8. Friedrichsen M et al. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes Obesity and Metabolism. 2021.
9. Elkind-Hirsch K et al. Comparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in overweight women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism. 2008.
10. Miras AD et al. Gastric bypass surgery for obesity decreases the reward value of a sweet-fat stimulus as assessed in a progressive ratio task. American Journal of Clinical Nutrition. 2012.
11. Wadden TA et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA. 2021.
12. Weghuber D et al. Once-Weekly Semaglutide in Adolescents with Obesity. New England Journal of Medicine. 2022.
13. American College of Gastroenterology. Clinical Guideline: Management of Obesity. 2022.
14. Garvey WT et al. American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. Endocrine Practice. 2016.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.